Growth Hormone Deficiency - Pipeline Review, H2 2015

Date: October 14, 2015
Pages: 111
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GC4D818DF3DEN
Leaflet:

Download PDF Leaflet

Growth Hormone Deficiency - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Growth Hormone Deficiency - Pipeline Review, H2 2015’, provides an overview of the Growth Hormone Deficiency’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Growth Hormone Deficiency pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Growth Hormone Deficiency
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Deficiency pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Growth Hormone Deficiency Overview
Therapeutics Development
Pipeline Products for Growth Hormone Deficiency - Overview
Pipeline Products for Growth Hormone Deficiency - Comparative Analysis
Growth Hormone Deficiency - Therapeutics under Development by Companies
Growth Hormone Deficiency - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Growth Hormone Deficiency - Products under Development by Companies
Growth Hormone Deficiency - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc.
Aileron Therapeutics, Inc.
Ascendis Pharma A/S
Biogenomics Limited
Bolder Biotechnology, Inc.
Braasch Biotech LLC
Carlina Technologies SAS
Critical Pharmaceuticals Limited
Delpor, Inc.
Flamel Technologies S.A.
Genexine, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Inbiopro Solutions Pvt. Ltd.
JCR Pharmaceuticals Co., Ltd.
LG Life Sciences Limited
OPKO Health, Inc.
Pfenex Inc.
Prometheon Pharma, LLC
Teva Pharmaceutical Industries Limited
Versartis, Inc.
XL-protein GmbH
Growth Hormone Deficiency - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
albutropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALRN-5281 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBT-031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-016 SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-024 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GXH-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-032 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HM-10560A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBPB-003HH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOD-4023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegylated Somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatotropin SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatotropin SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin pegol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somatropin SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
somavaratan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Growth Hormone Deficiencies - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XL-020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Growth Hormone Deficiency - Recent Pipeline Updates
Growth Hormone Deficiency - Dormant Projects
Growth Hormone Deficiency - Discontinued Products
Growth Hormone Deficiency - Product Development Milestones
Featured News & Press Releases
Oct 01, 2015: Versartis Presents Confirmatory 18-Month Data From Ongoing Somavaratan Extension Study at Late-Breaker Session at ESPE Annual Meeting
Sep 18, 2015: Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Somavaratan in GHD Children
Sep 10, 2015: Versartis Initiates Phase 2 Trial of Monthly Somavaratan in Adults With Growth Hormone Deficiency
Sep 08, 2015: Versartis Announces Agenda and Event Details for Investor Symposium Featuring Global Opinion Leaders in Pediatric Human Growth Hormone Deficiency
Aug 05, 2015: Two Reports on hGH-CTP Pediatric Phase 2 Clinical Data Accepted for Oral Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology
Aug 04, 2015: Versartis Abstract Accepted for Late-Breaker Presentation at the 54th Annual Meeting of the European Society for Paediatric Endocrinology
Jul 30, 2015: Ascendis Pharma Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
Jul 10, 2015: Opko Announces Completion Of Enrollment In Phase 3 Trial Of Hgh-Ctp In Growth Hormone Deficient Adults
Jul 06, 2015: Versartis Announces Removal of FDA Partial Clinical Hold and Continuation of VRS-317 Phase 3 Clinical Trial
Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Growth Hormone Deficiency, H2 2015
Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Growth Hormone Deficiency - Pipeline by Aeterna Zentaris Inc., H2 2015
Growth Hormone Deficiency - Pipeline by Aileron Therapeutics, Inc., H2 2015
Growth Hormone Deficiency - Pipeline by Ascendis Pharma A/S, H2 2015
Growth Hormone Deficiency - Pipeline by Biogenomics Limited, H2 2015
Growth Hormone Deficiency - Pipeline by Bolder Biotechnology, Inc., H2 2015
Growth Hormone Deficiency - Pipeline by Braasch Biotech LLC, H2 2015
Growth Hormone Deficiency - Pipeline by Carlina Technologies SAS, H2 2015
Growth Hormone Deficiency - Pipeline by Critical Pharmaceuticals Limited, H2 2015
Growth Hormone Deficiency - Pipeline by Delpor, Inc., H2 2015
Growth Hormone Deficiency - Pipeline by Flamel Technologies S.A., H2 2015
Growth Hormone Deficiency - Pipeline by Genexine, Inc., H2 2015
Growth Hormone Deficiency - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Growth Hormone Deficiency - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Growth Hormone Deficiency - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Growth Hormone Deficiency - Pipeline by JCR Pharmaceuticals Co., Ltd., H2 2015
Growth Hormone Deficiency - Pipeline by LG Life Sciences Limited, H2 2015
Growth Hormone Deficiency - Pipeline by OPKO Health, Inc., H2 2015
Growth Hormone Deficiency - Pipeline by Pfenex Inc., H2 2015
Growth Hormone Deficiency - Pipeline by Prometheon Pharma, LLC, H2 2015
Growth Hormone Deficiency - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Growth Hormone Deficiency - Pipeline by Versartis, Inc., H2 2015
Growth Hormone Deficiency - Pipeline by XL-protein GmbH, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Growth Hormone Deficiency Therapeutics - Recent Pipeline Updates, H2 2015
Growth Hormone Deficiency - Dormant Projects, H2 2015
Growth Hormone Deficiency - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Growth Hormone Deficiency, H2 2015
Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Aeterna Zentaris Inc.
Aileron Therapeutics, Inc.
Ascendis Pharma A/S
Biogenomics Limited
Bolder Biotechnology, Inc.
Braasch Biotech LLC
Carlina Technologies SAS
Critical Pharmaceuticals Limited
Delpor, Inc.
Flamel Technologies S.A.
Genexine, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Inbiopro Solutions Pvt. Ltd.
JCR Pharmaceuticals Co., Ltd.
LG Life Sciences Limited
OPKO Health, Inc.
Pfenex Inc.
Prometheon Pharma, LLC
Teva Pharmaceutical Industries Limited
Versartis, Inc.
XL-protein GmbH
Skip to top


Ask Your Question

Growth Hormone Deficiency - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: